tetano
Editor, Senior Moderator
Cell Rep
. 2023 Jan 27;42(2):112075.
doi: 10.1016/j.celrep.2023.112075. Online ahead of print.
Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
Ka-Li Zhu[SUP] 1 [/SUP], Xiao-Lin Jiang[SUP] 2 [/SUP], Bing-Dong Zhan[SUP] 3 [/SUP], Xue-Jun Wang[SUP] 4 [/SUP], Xian Xia[SUP] 5 [/SUP], Guo-Ping Cao[SUP] 3 [/SUP], Wen-Kui Sun[SUP] 2 [/SUP], Peng-Xiang Huang[SUP] 2 [/SUP], Jin-Zhong Zhang[SUP] 6 [/SUP], Yu-Ling Gao[SUP] 7 [/SUP], Er-Hei Dai[SUP] 7 [/SUP], Hui-Xia Gao[SUP] 8 [/SUP], Mai-Juan Ma[SUP] 9 [/SUP]
Affiliations
Abstract
Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF.7, BQ.1.1, and XBB against neutralizing antibodies from vaccination, hybrid immunity, and breakthrough infections 4-6 months after vaccination and infection. We show that a two-dose CoronaVac or a third-dose ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after vaccination. Hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections induce long-term persistence of the antibody response, and over 70% of sera neutralize BA.1, BA.2, BA.4/BA.5, and BF.7. However, BQ.1.1 and XBB, followed by BA.2.75, are more resistant to neutralization, with neutralizing titer reductions of ∼9- to 41-fold, ∼16- to 63-fold, and ∼4- to 25-fold, respectively. These data highlight additional vaccination in CoronaVac- or ZF2001-vaccinated individuals and provide insight into the durability of neutralization against Omicron subvariants.
Keywords: CP: Immunology; CP: Microbiology; Omicron subvariants; booster vaccination; breakthrough infection; hybrid immunity; immune evasion; neutralization.
. 2023 Jan 27;42(2):112075.
doi: 10.1016/j.celrep.2023.112075. Online ahead of print.
Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
Ka-Li Zhu[SUP] 1 [/SUP], Xiao-Lin Jiang[SUP] 2 [/SUP], Bing-Dong Zhan[SUP] 3 [/SUP], Xue-Jun Wang[SUP] 4 [/SUP], Xian Xia[SUP] 5 [/SUP], Guo-Ping Cao[SUP] 3 [/SUP], Wen-Kui Sun[SUP] 2 [/SUP], Peng-Xiang Huang[SUP] 2 [/SUP], Jin-Zhong Zhang[SUP] 6 [/SUP], Yu-Ling Gao[SUP] 7 [/SUP], Er-Hei Dai[SUP] 7 [/SUP], Hui-Xia Gao[SUP] 8 [/SUP], Mai-Juan Ma[SUP] 9 [/SUP]
Affiliations
- PMID: 36774551
- DOI: 10.1016/j.celrep.2023.112075
Abstract
Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF.7, BQ.1.1, and XBB against neutralizing antibodies from vaccination, hybrid immunity, and breakthrough infections 4-6 months after vaccination and infection. We show that a two-dose CoronaVac or a third-dose ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after vaccination. Hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections induce long-term persistence of the antibody response, and over 70% of sera neutralize BA.1, BA.2, BA.4/BA.5, and BF.7. However, BQ.1.1 and XBB, followed by BA.2.75, are more resistant to neutralization, with neutralizing titer reductions of ∼9- to 41-fold, ∼16- to 63-fold, and ∼4- to 25-fold, respectively. These data highlight additional vaccination in CoronaVac- or ZF2001-vaccinated individuals and provide insight into the durability of neutralization against Omicron subvariants.
Keywords: CP: Immunology; CP: Microbiology; Omicron subvariants; booster vaccination; breakthrough infection; hybrid immunity; immune evasion; neutralization.